Crossmark

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Crossref DOI link: https://doi.org/10.1186/S12885-017-3626-5

Published: 2017-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

van der Hiel, Bernies http://orcid.org/0000-0001-8158-405X
,

Haanen, John B.A.G.

Stokkel, Marcel P.M.

Peeper, Daniel S.

Jimenez, Connie R.

Beijnen, Jos H.

van de Wiel, Bart A.

Boellaard, Ronald

van den Eertwegh, Alfons J.M.
Funding

Funding for this research was provided by:

F. Hoffman-La Roche

Document is current

Any future updates will be listed below